Axolabs
Christoph Maier is currently a Thesis Student at MTU Aero Engines, engaged in a research project focusing on Additive Manufacturing, starting April 2024. Previously, Christoph worked as a Working Student in Product Management at EOS, where responsibilities included revising machine documentation and conducting market analysis for 3D printing systems. At the Technische Universität München, experience included roles as a Student Assistant at the Chair of Laser-based Additive Manufacturing, where Christoph contributed to the design and development of a topology optimized demonstrator part, and at the Chair of Materials Handling, Material Flow, and Logistics, providing tutoring in computer-aided design. An internship at BMW Group involved developing tools for process data analysis, quality assessment, and data visualization. Earlier experience included an engineering internship at CIM med GmbH. Christoph Maier is pursuing a Master of Science in Mechanical Engineering at the Technical University of Munich and has previously earned a Bachelor of Science in Mechanical Engineering from the same institution, with an additional academic experience at Sogang University.
This person is not in the org chart
This person is not in any offices
Axolabs
Axolabs specialises in a new class of drugs whose active ingredients are chemically derived from DNA or RNA. They are called oligonucleotide or nucleic acid therapeutics. We use our many years of expertise to help our clients make them a success. Some of these drugs have already been approved and are being used successfully against diseases that were previously untreatable in some cases. New drugs from this class are added every year. Axolabs is part of the LGC Group. Its business unit for nucleic acid therapeutics is combined under the brand name Axolabs. Axolabs operates companies in the following locations: Axolabs, Kulmbach, Germany Axolab Kulmbach GmbH, is the world’s leading custom research organization in the field of nucleic acid therapeutics with a wide range of services. Axolabs Berlin, Berlin, Germany Axolabs Berlin is currently establishing a new site in Berlin for GMP manufacturing of nucleic acid therapeutics. The site will be dedicated to medium to large scale and early to late phase clinical GMP manufacturing of nucleic acid therapeutics. The state-of-the-art facility will deliver integrated analytical and manufacturing solutions. The operational start date is scheduled for 2024. Axolabs Petaluma, Petaluma, California, USA Axolabs operates a cGMP production facility in Petaluma for oligonucleotide compounds for technical, toxicological and preclinical to late-stage clinical trials. Services: bioinformatics, oligonucleotide synthesis, analytics and in vitro / in vivo analysis.